Inventor · disambiguated record
Peter Vanderslice
Also filed as: VANDERSLICE PETER
12 granted patents·3 pending applications·210 citations·filing 1994–2021
90Inventor score
Files with7 Hills Pharma LLC4TEXAS BIOTECHNOLOGY CORP3TEXAS HEART INST37 HILLS INTERESTS LLC17 HILLS PHARMA INC1
Top patents by PatentIndex Score
15 records- 0192US5510332AProcess to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides thereforTEXAS BIOTECHNOLOGY CORP·Filed 1994·Granted Apr 23, 1996·151 cites·15 claims
- 0289US11311619B2Integrin activator vaccine compositions7 Hills Pharma LLC·Filed 2020·Granted Apr 26, 2022·2 cites·20 claims
- 0388US10716849B2Methods of administering novel integrin activator vaccine compositions7 Hills Pharma LLC·Filed 2019·Granted Jul 21, 2020·3 cites·20 claims
- 0488US10709781B2Integrin activator checkpoint inhibitor compositions7 Hills Pharma LLC·Filed 2019·Granted Jul 14, 2020·2 cites·16 claims
- 0588US10709780B2Integrin activator vaccine compositions7 Hills Pharma LLC·Filed 2019·Granted Jul 14, 2020·3 cites·20 claims
- 0683US10342866B2Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants7 HILLS INTERESTS LLC·Filed 2016·Granted Jul 9, 2019·5 cites·23 claims
- 0778US9512109B2Agonists that enhance binding of integrin-expressing cells to integrin receptorsBIEDIGER RONALD J·Filed 2011·Granted Dec 6, 2016·4 cites·1 claims
- 0875US6087330AProcess to inhibit binding of the integrin α4 β1 to VCAM-1 or fibronectin and cyclic peptides thereforTEXAS BIOTECHNOLOGY CORP·Filed 1998·Granted Jul 11, 2000·33 cites·17 claims
- 0969US12201686B2Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound7 HILLS PHARMA INC·Filed 2021·Granted Jan 21, 2025·0 cites·18 claims
- 1057US10287264B2Agonists that enhance binding of integrin-expressing cells to integrin receptorsTEXAS HEART INST·Filed 2016·Granted May 14, 2019·0 cites·8 claims
- 1153US2021393811A1Imaging Agents and Methods of UseTEXAS HEART INST·Filed 2019·Application pending·0 cites
- 1249US6713604B1Process to inhibit binding of the integrin α4β1 , to VCAM-1 fibronectin and cyclic peptides thereofTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Mar 30, 2004·7 cites·4 claims
- 1344US2007060608A1Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compoundsSCHERING CORP·Filed 2003·Application pending·0 cites
- 1440US11312685B2Targeting nanoparticlesTEXAS CHILDRENS HOSPTIAL·Filed 2018·Granted Apr 26, 2022·0 cites·56 claims
- 1531US2017042985A1Methods of using cyclooxygenase-prostacyclin synthase fusion geneTEXAS HEART INST·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Vanderslice files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →